Impact News +++ Fujikura legt Mittelfristplan vor und strebt operativen Gewinn von 580 Mrd. Yen an (Investing.com DE) +++ FUJIKURA Aktie -3,38%

INMED Aktie

>INMED Aktienkurs

1.37 EUR +132.2% (TradegateBSX)

Ask: 1.23 EUR / 0 Stück

Bid: 1.18 EUR / 0 Stück

Tagesumsatz: 12412 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INMED Aktie über LYNX handeln

Intraday

1 Jahr

>INMED Performance

1 Woche: +8,3%

1 Monat: -2,5%

3 Monate: -20,3%

6 Monate: -58,0%

1 Jahr: -77,8%

laufendes Jahr: -40,1%

>INMED Aktie

Name:

INMED PHARMACEUTICALS

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA4576377002 / A40UCN

Symbol/ Ticker:

MWG (Frankfurt) / INM (NASDAQ)

Kürzel:

FRA:MWG, ETR:MWG, MWG:GR, NASDAQ:INM

Index:

Webseite:

https://www.inmedpharma.c..

Profil:

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada. The company focuses on researching and developing cannabinoid-based pharmaceutical products targeting diseases with high unmet medical needs, particu..
>Volltext..

Marktkapitalisierung:

1.82 Mio. EUR

Unternehmenswert:

-2.33 Mio. EUR

Umsatz:

2.79 Mio. EUR

EBITDA:

-6.85 Mio. EUR

Nettogewinn:

-7.32 Mio. EUR

Gewinn je Aktie:

-2.22 EUR

Schulden:

0.36 Mio. EUR

Liquide Mittel:

4.44 Mio. EUR

Operativer Cashflow:

Bargeldquote:

2.35

Umsatzwachstum:

-38.25%

Gewinnwachstum:

4.13%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INMED

Letzte Datenerhebung:

19.05.26

>INMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 3.31 Mio. St.

Frei handelbar: 99.83%

Leerverk. Aktien: 1.07%

Rückkaufquote: -399.32%

Mitarbeiter: 13

Umsatz/Mitarb.: 0.33 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 1.13

KBV: 0.36

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 17.98%

Gewinnmarge: -256.86%

Operative Marge: -263.26%

Managementeffizenz:

Gesamtkaprendite: -90.53%

Eigenkaprendite: -119.82%

>INMED Peer Group

Gesundheit, Augenmedizin, Hauterkrankungen & -behandlung/ Dermatologie, Neurologie/ psychische Behandlung/ Schlaganfälle

>INMED Chart & Kurs - NASDAQ

>INMED News

19.05.26 - 15:45	XFRA: MWG: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN INMED PHARMACEUT.INC.NEW MWG CA4576377002 AB/FROM ONWARDS 19.05.2026 15:28 CET...

19.05.26 - 14:57	InMed and Mentari announce all-stock merger deal (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.05.26 - 14:33	XFRA: INSTRUMENT_SUSPENSION - CA4576377002 (XETRA)
	Instrument ID [21629377] (MWG - CA4576377002) suspended...

19.05.26 - 14:33	XFRA: MWG: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL INMED PHARMACEUT.INC.NEW MWG CA4576377002 BAW/UFN...

19.05.26 - 14:01	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies (PR Newswire)
	Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations......

19.05.26 - 12:06	InMed Pharmaceuticals: InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro......

07.05.26 - 00:12	InMed Pharmaceuticals: InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop......

27.04.26 - 23:42	InMed Pharmaceuticals: InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of p......

27.03.26 - 22:18	InMed Pharmaceuticals: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modi......

27.03.26 - 22:15	InMed Pharma gets Nasdaq non-compliance notice (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.03.26 - 12:42	InMed Pharmaceuticals: InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer′s Disease Program (Newsfile)
	Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Di......

09.03.26 - 12:42	InMed Pharmaceuticals: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial (Newsfile)
	Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Va......

06.03.26 - 23:24	InMed Pharmaceuticals: InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of di......

11.02.26 - 23:36	InMed Pharmaceuticals: InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on develo......

18.12.25 - 02:06	InMed Pharmaceuticals: InMed Announces Results of 2025 Annual General and Special Meeting (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline o......

12.12.25 - 23:42	InMed Pharmaceuticals: InMed Provides Update on BayMedica Commercial Business (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline o......

20.11.25 - 08:36	What′s Driving InMed′s (INM) 22% After-Hours Surge? (Benzinga)
	InMed shares jumped 22% in after-hours trading after the company reported encouraging large-animal study results for its Alzheimer's drug candidate INM-901. read more...

18.11.25 - 13:42	InMed Pharmaceuticals: InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer′s Disease Candidate INM-901 (Newsfile)
	Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA Va......

07.11.25 - 00:00	InMed Pharmaceuticals GAAP EPS of -$0.44 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 23:12	InMed Pharmaceuticals: InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on develop......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Veni, vidi, vici - Ich kam, ich sah, ich siegte. (Caesar über die Schlacht bei Zela gegen Pharnakos II., 47 v. Chr.). - Gajus Julius Caesar

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram